A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter
study looking at the response rate of patients receiving selinexor (KPT-330), in combination
with carfilzomib, daratumumab or pomalidomide.
Multiple Myeloma patients with documented disease progression or refractory disease while on
current treatment with any carfilzomib-containing regimen (arm 1), any
pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory
arm) will be included in the study. Patients will be assigned to the respective groups
according to their current treatment. If a subject has received more than one of the above
therapies, then assignment will be made at their physician's discretion (e.g treatment
decision can be made based upon patient and physician preferred tolerance.).
Patients will receive treatment until progressive disease (PD), death, toxicity that cannot
be managed by standard of care, or withdrawal, whichever occurs first.